首页> 外文期刊>Hematology/Oncology Clinics of North America >Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us.
【24h】

Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us.

机译:造血干细胞移植治疗严重的联合免疫缺陷或孩子们教给我们的知识。

获取原文
获取原文并翻译 | 示例
           

摘要

It is now more than 40 years since the first successful allogeneic hematopoietic stem cell transplantation (HSCT) for a child with severe combined immunodeficiency (SCID). In the succeeding years, HSCT for SCID patients have represented only a small portion of the total number of allogeneic HSCT performed. Nevertheless, the clinical and biologic importance of the patients transplanted for SCID has continued. SCID patients were the first to be successfully transplanted with nonsibling related bone marrow, unrelated bone marrow, T-cell depleted HSCT, and genetically corrected (gene transfer) autologous HSC. Many of the biologic insights now widely applied to allogeneic HSCT were first identified in the transplantation of SCID patients. This article reviews the clinical and biologic lessons that have been learned from HSCT for SCID patients, and how the information has impacted the general field of allogeneic HSCT.
机译:自从首次成功为患有严重合并免疫缺陷症(SCID)的儿童进行异基因造血干细胞移植(HSCT)以来,已有40多年的历史了。在随后的几年中,SCID患者的HSCT仅占异基因HSCT总数的一小部分。尽管如此,移植SCID患者的临床和生物学重要性仍在继续。 SCID患者是第一个成功移植无兄弟相关骨髓,无关骨髓,T细胞耗竭的HSCT以及基因校正(基因转移)自体HSC的患者。现在广泛应用于同种异体造血干细胞移植的许多生物学见解首先是在SCID患者的移植中发现的。本文回顾了从HSCT中为SCID患者获得的临床和生物学课程,以及这些信息如何影响同种异体HSCT的整个领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号